QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
Log in
NASDAQ:VNDA

Vanda Pharmaceuticals Stock Forecast, Price & News

$19.35
-0.93 (-4.59 %)
(As of 02/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.20
Now: $19.35
$20.51
50-Day Range
$13.73
MA: $15.56
$20.28
52-Week Range
$7.12
Now: $19.35
$20.51
Volume449,266 shs
Average Volume609,194 shs
Market Capitalization$1.06 billion
P/E Ratio53.75
Dividend YieldN/A
Beta0.56
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, and delayed sleep phase disorder; Fanapt® (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Vanda Pharmaceuticals logo

Headlines

Return On Capital Employed Overview: Vanda Pharmaceuticals
February 11, 2021 |  finance.yahoo.com
Recap: Vanda Pharmaceuticals Q4 Earnings
February 10, 2021 |  benzinga.com
VNDA Jan 2021 12.000 put
December 21, 2020 |  uk.finance.yahoo.com
VNDA Jan 2021 13.000 put
December 21, 2020 |  uk.finance.yahoo.com
VNDA Jan 2021 12.000 call
December 20, 2020 |  uk.finance.yahoo.com
Is VNDA A Good Stock To Buy Now According To Hedge Funds?
December 19, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VNDA
CUSIP92165910
Phone202-734-3400
Employees284
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$227.19 million
Cash Flow$2.99 per share
Book Value$7.70 per share

Profitability

Net Income$115.55 million

Miscellaneous

Market Cap$1.06 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.46 out of 5 stars

Medical Sector

482nd out of 1,957 stocks

Pharmaceutical Preparations Industry

241st out of 771 stocks

Analyst Opinion: 1.1Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
$19.35
-0.93 (-4.59 %)
(As of 02/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VNDA News and Ratings via Email

Sign-up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions

Is Vanda Pharmaceuticals a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Vanda Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VNDA, but not buy additional shares or sell existing shares.
View analyst ratings for Vanda Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Vanda Pharmaceuticals?

Wall Street analysts have given Vanda Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Vanda Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Vanda Pharmaceuticals' next earnings date?

Vanda Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Vanda Pharmaceuticals
.

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced its quarterly earnings data on Wednesday, February, 10th. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.05. Vanda Pharmaceuticals had a trailing twelve-month return on equity of 4.56% and a net margin of 8.02%.
View Vanda Pharmaceuticals' earnings history
.

How has Vanda Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Vanda Pharmaceuticals' stock was trading at $10.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VNDA shares have increased by 82.5% and is now trading at $19.35.
View which stocks have been most impacted by COVID-19
.

What guidance has Vanda Pharmaceuticals issued on next quarter's earnings?

Vanda Pharmaceuticals updated its FY 2021 After-Hours earnings guidance on Wednesday, February, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $270-300 million, compared to the consensus revenue estimate of $279.4 million.

What price target have analysts set for VNDA?

7 analysts have issued 1-year price targets for Vanda Pharmaceuticals' shares. Their forecasts range from $12.00 to $25.00. On average, they anticipate Vanda Pharmaceuticals' share price to reach $16.29 in the next twelve months. This suggests that the stock has a possible downside of 15.8%.
View analysts' price targets for Vanda Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Vanda Pharmaceuticals' key executives?

Vanda Pharmaceuticals' management team includes the following people:
  • Dr. Mihael H. Polymeropoulos, Founder, Pres, CEO & Director (Age 61, Pay $1.43M)
  • Mr. Timothy Williams, Sr. VP, Gen. Counsel & Sec. (Age 45, Pay $599.18k)
  • Mr. Gunther Birznieks, Sr. VP of Bus. Devel. (Age 52, Pay $587.14k)
  • Mr. Kevin Patrick Moran, Acting CFO, VP & Treasurer (Age 37)
  • Mr. Aranthan Jones II, Chief Corp. Affairs & Communications Officer (Age 45)
  • Mr. Joakim Wijkstrom, Sr. VP & Chief Marketing Officer (Age 55)
  • Mr. Scott L. Howell, Chief People Officer
  • Ms. Elizabeth Van Every, Head of Corp. Affairs

What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO?

12 employees have rated Vanda Pharmaceuticals CEO Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among Vanda Pharmaceuticals' employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Vanda Pharmaceuticals' key competitors?

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX).

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (17.95%), Armistice Capital LLC (9.87%), Renaissance Technologies LLC (7.30%), Dimensional Fund Advisors LP (2.83%), Morgan Stanley (1.64%) and Northern Trust Corp (1.19%). Company insiders that own Vanda Pharmaceuticals stock include Aranthan Jones II, Gian Piero Reverberi, James Patrick Kelly, Joakim Wijkstrom, Mihael Hristos Polymeropoulos, Richard W Dugan, Thomas Watkins and Timothy Williams.
View institutional ownership trends for Vanda Pharmaceuticals
.

Which major investors are selling Vanda Pharmaceuticals stock?

VNDA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, SG Americas Securities LLC, Russell Investments Group Ltd., Armistice Capital LLC, Public Sector Pension Investment Board, ClariVest Asset Management LLC, Trexquant Investment LP, and Northern Trust Corp. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Aranthan Jones II, Joakim Wijkstrom, Mihael Hristos Polymeropoulos, Richard W Dugan, Thomas Watkins, and Timothy Williams.
View insider buying and selling activity for Vanda Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Vanda Pharmaceuticals stock?

VNDA stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., JPMorgan Chase & Co., M&G Investment Management Ltd., Dimensional Fund Advisors LP, Jackson Creek Investment Advisors LLC, Royce & Associates LP, and Prairiewood Capital LLC.
View insider buying and selling activity for Vanda Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vanda Pharmaceuticals' stock price today?

One share of VNDA stock can currently be purchased for approximately $19.35.

How much money does Vanda Pharmaceuticals make?

Vanda Pharmaceuticals has a market capitalization of $1.06 billion and generates $227.19 million in revenue each year. The biopharmaceutical company earns $115.55 million in net income (profit) each year or $2.11 on an earnings per share basis.

How many employees does Vanda Pharmaceuticals have?

Vanda Pharmaceuticals employs 284 workers across the globe.

What is Vanda Pharmaceuticals' official website?

The official website for Vanda Pharmaceuticals is www.vandapharma.com.

Where are Vanda Pharmaceuticals' headquarters?

Vanda Pharmaceuticals is headquartered at 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]


This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.